Chemesis International Inc. Provides Corporate Update

Cannabis Investing News
CSE:CSI

Chemesis International Inc. (CSE:CSI, OTCQB:CADMF, FRA:CWAB) (the “Company” or “Chemesis”), is pleased to announce, further to its news release dated January 27, 2020, that the Puerto Rico Department of Health (the “DHPR”), as a result of the previously announced favourable judgment from the Puerto Rico Superior Court, San Juan (the “Decision”) (please see the news …

Chemesis International Inc. (CSE:CSI, OTCQB:CADMF, FRA:CWAB) (the “Company” or “Chemesis”), is pleased to announce, further to its news release dated January 27, 2020, that the Puerto Rico Department of Health (the “DHPR”), as a result of the previously announced favourable judgment from the Puerto Rico Superior Court, San Juan (the “Decision”) (please see the news release dated January 17, 2020), has reinstated all cannabis cultivation and cannabis manufacturing licenses (the “Licenses”) held by its subsidiary, Natural Ventures PR, LLC (“Natural Ventures”). The Decision, which is still under appeal, found that such abeyance of the Licenses was invalid and unconstitutional and nullified such action.

The Company notes that, at the current time, the Licenses have been reinstated to being operational, and that Natural Ventures is permitted to carry out the licensed activities under the Licenses. The Company will provide further updates as appropriate.

On Behalf of The Board of Directors

Edgar Montero

CEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands that cater to a wide community of cannabis consumers, with focus on quality and consistency.

Chemesis has facilities in both Puerto Rico and California. The Company is positioned to win additional licenses in highly competitive merit-based US states and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:

ir@chemesis.com
1 (604) 398-3378

Social Media:

Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
GreenSpiritRX

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing, the outcome of the appeal, its plans to continue to develop dispensaries in Puerto Rico, and its ability to obtain licenses in additional jurisdictions. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Decision may be successfully appealed by the Puerto Rico Department of Health, the appeal may not be resolved promptly, that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected, including, but not limited to, in relation to developing dispensaries in Puerto Rico, and its ability to obtain licenses in additional jurisdictions. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

 

Click here to connect with Chemesis International Inc. (CSE:CSI) for an Investor Presentation.

Source

 

The Conversation (0)
×